GemVax Pancreatic Cancer Vaccine Set For First Launch, By Samsung
This article was originally published in PharmAsia News
Despite an earlier Phase III setback for its therapeutic pancreatic cancer vaccine Riavax, GemVax & KAEL Co. has signed a new licensing deal with Samsung Pharm under which the latter will handle manufacturing, supplying and commercializing of the first-in-class product in South Korea.
You may also be interested in...
Medifron DBT's plan to make a sizable investment in its Alzheimer’s disease drug pipelines may be followed by further South Korean biotechs and pharmas accelerating development in the field as the country steps up support for dementia R&D.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.